45
Views
5
CrossRef citations to date
0
Altmetric
Research Article

PERCEPTUAL REACTANCE, DRUG PREFERENCE, AND ELECTRODERMAL ACTIVITY IN TREATMENT-SEEKING SUBSTANCE ABUSERS

Pages 109-125 | Published online: 09 Jul 2009
 

Abstract

Perceptual reactance (PR) was explored as a contributing variable to drug abuse. PR is defined as the general tendency of an individual's central nervous system to perceptually modulate incoming sensory stimuli. Using an adaptive model of drug use, it was hypothesized that drug preference in substance abusers would vary with PR. Specifically, perceptual reducers, who subjectively dampen afferent sensation, would prefer experience-expanding drugs (i.e., cocaine and amphetamines) to heighten perception. Conversely, perceptual augmenters would prefer sensory-restricting drugs (i.e., opioids and sedative-hypnotics) that attenuate or modulate environmental stimuli. Utilizing subjective (Reducing-Augmenting Scale) and objective (electrodermal responses) measures of PR, the relationship was tested in a sample of treatment-seeking substance abusers (n = 122). The sample was stratified on whether or not they were abstinent. Interestingly, a higher than anticipated rate of electrodermal nonresponsivity was found across the sample and the implications of this finding are discussed. The study hypothesis was only supported in the electrodermally-responsive group.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.